- Home
- PRLD
as 03-28-2025 4:00pm EST
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | 73.7M | IPO Year: | 2020 |
| Target Price: | $4.50 | AVG Volume (30 days): | 206.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.68 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.63 - $6.80 | Next Earning Date: | 03-10-2025 |
| Revenue: | $7,000,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Prelude Therapeutics Incorporated (PRLD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Vaddi Krishna | PRLD | CEO | Mar 20 '25 | Buy | $0.73 | 20,416 | $14,909.43 | 1,309,296 | |
| Vaddi Krishna | PRLD | CEO | Mar 14 '25 | Buy | $0.75 | 39,105 | $29,459.84 | 1,309,296 | |
| Vaddi Krishna | PRLD | CEO | Mar 12 '25 | Buy | $0.71 | 97,500 | $69,564.00 | 1,309,296 | |
| Vaddi Krishna | PRLD | CEO | Dec 31 '24 | Buy | $1.21 | 5,000 | $6,043.50 | 1,309,296 | |
| Vaddi Krishna | PRLD | CEO | Dec 30 '24 | Buy | $1.20 | 10,000 | $12,000.00 | 1,309,296 |
Latest Prelude Therapeutics Incorporated News
PRLD Breaking Stock News: Dive into PRLD Ticker-Specific Updates for Smart Investing
Argus Research
a day ago
Daily – Vickers Top Insider Picks for 03/28/2025
Argus Research
a day ago
Daily – Vickers Top Buyers & Sellers for 03/28/2025
Argus Research
10 days ago
Daily – Vickers Top Insider Picks for 03/19/2025
Argus Research
12 days ago
Daily – Vickers Top Insider Picks for 03/17/2025
GlobeNewswire
19 days ago
Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025
GlobeNewswire
24 days ago
Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference
Simply Wall St.
25 days ago
We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully
Simply Wall St.
2 months ago
US Penny Stocks To Watch In January 2025
Compare PRLD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRLD Prelude Therapeutics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.